Polycythemia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycythemia}} | {{Polycythemia}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Debduti}} | ||
==Overview== | ==Overview== | ||
Line 12: | Line 12: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category:Hematology]] | ||
[[Category:Emergency medicine]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Blood disorders]] | [[Category:Blood disorders]] | ||
[[Category: | [[Category:Up-To-Date]] |
Revision as of 21:14, 24 September 2020
Polycythemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Polycythemia cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Polycythemia cost-effectiveness of therapy |
Risk calculators and risk factors for Polycythemia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]